Innovations in CNS

Summary

The CNS drug market presents significant profit opportunities, but also carries high risks for companies aiming to achieve blockbuster status. Pipelines based on novel molecular targets to treat underlying disease promise to transform the treatment of psychiatric and neurological diseases, however research and development of these drugs requires an innovative approach to ensure investment is maximized.

Innovations in CNS: Novel therapeutics and future R&D strategies assesses novel treatments in development for major CNS disorders, comparing them with existing medications in terms of unmet need and forecasting their success in the commercial market. This report will enable you to understand the research tactics of your competitors and develop winning strategies for future growth in the lucrative CNS market. The report provides a survey of the pipelines of all of the major players in the CNS area. Detailed company profiles featured in the report include: AstraZeneca, GlaxoSmithKline, Merck & Co, Pfizer, and Sanofi-Aventis.

Use this report to understand the factors that will ensure your product pipeline achieves clinical and commercial success and analyze the product pipelines of the leading companies in the CNS market.

Key findings of the report...

• CNS pipelines show an unprecedented level of novelty against the industry trend of fewer new mechanisms making it to the market.
• Early signs of the long awaited impact of molecular biological technology in the CNS area are positive, with antibodies for Alzheimer's disease beginning to make real progress.
• Companies are moving away from merely treating symptoms to looking for interventions that treat the underlying disease state for conditions such as Alzheimer's and Parkinson's diseases.
• In spite of some early failures companies are still investing enormous resources in bringing NK-1 (Substance P) antagonists through clinical development.
• The success of antagonists for NK-2 or NK-3 receptors for the treatment of psychoses is likely to open up intense activity in that area as companies strive to catch up with the current leaders.
• Company size does not relate to level of novelty in pipelines. Large companies vary hugely in the level of innovation in their pipelines and small companies can compete in the blockbuster arena with innovative molecules.

Key questions answered in this report

• What indications will see an increase in innovative launches in the next few years?
• Which companies will become key players in the CNS market?
• What roles will big pharma and SME/biotech companies play in the future of CNS treatment?
• Is molecular biology only an enabling technology in CNS drug discovery?
• What does the future of hold for CNS blockbuster drugs?
• Which pipeline products feature highest growth potential and why?
• What are the key unmet needs within the major sub-indications of depression, anxiety, schizophrenia, sleep disorders, Alzheimer's, movement disorders and pain?

Top five reasons to order your copy today

• Analyze patient potential, economic burden and key unmet needs in 10 major CNS disorders across the US, EU and Japan, including schizophrenia, depression and Alzheimer's disease.
• Understand how key preclinical and clinical trials are impacting CNS drug development, enabling you to assess new innovations and anticipate future trends in the market.
• Assess your organisation's position in the market-place, and develop innovative future strategies to ensure you are positioned for success.
• Discover novel treatment strategies for all major therapeutic areas in psychaitry and neurology.
• Gain access to the CNS pipelines of leading companies including Sanofi-Aventis, Pfizer and AstraZeneca to understand their differing portfolio management strategies.

Content